ScholarIQanswers from OpenAlex
Cancer Immunotherapy and Biomarkers
TopicLeading institutions, researchers & key papers
Cancer Immunotherapy and Biomarkers is a topic indexed in ScholarIQ from OpenAlex.
What is known about Cancer Immunotherapy and Biomarkers?
ScholarIQrecord summary
This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting.
How many works does Cancer Immunotherapy and Biomarkers have?
ScholarIQindexed works
Cancer Immunotherapy and Biomarkers has 1,082 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Cancer Immunotherapy and Biomarkers?
ScholarIQopenalex
The OpenAlex for Cancer Immunotherapy and Biomarkers is on the source record.
What are the most-cited papers on Cancer Immunotherapy and Biomarkers?
ScholarIQmost cited works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, Valerie S. Barta, Gilbert Deray, Craig Devoe, Vincent Launay‐Vacher, Kenar D. Jhaveri, on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra Eyring, Andrew D. Skora, Brandon Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Díaz
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Where is Cancer Immunotherapy and Biomarkers research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Cancer Immunotherapy and Biomarkers is open access?
ScholarIQopen access share
80%OPEN ACCESS